抄録
TS-1, a novel oral antitumor agent, is composed of tegafur, prodrug of 5-FU, CDHP, inhibitor of 5-FU degradation and Oxo, inhibitor of 5-FU phospheribosylation. Recently, we administered TS-1 to 6 cases with oral cancer. This paper reports the results.
Four cases received TS-1 for 4 weeks followed by rest for 2 weeks, as one cycle. Two cases were given TS-1 for 3 weeks, and in addition CDDP (60mg/m2) on day 8, followed by 2 weeks of rest, as one cycle.
An advantage of TS-1 is that it can be administered to outpatients. In some cases, the agent appeared to be effective. Therefore we will continue to give our patients TS-1 for further clinical evaluation.
